IMMX IMMIX BIOPHARMA INC revenue, earnings and financials
For the quarter ended June 30, 2026, IMMIX BIOPHARMA INC reported revenue of n/a, net income of −$11.6M and diluted EPS of −$0.18; for the fiscal year ended December 2025 revenue was n/a.
IMMX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$30.0M, net income −$29.4M (margin n/a), EPS −$0.89
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$22.7M, net income −$21.6M (margin n/a), EPS −$0.76
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$16.1M, net income −$15.4M (margin n/a), EPS −$0.89
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$8.22M, net income −$8.23M (margin n/a), EPS −$0.59
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$1.35M, net income −$24.4M (margin n/a), EPS −$6.64
IMMX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$11.6M, EPS −$0.18
- Quarter ended Mar 31, 2026: revenue n/a, net income −$10.1M, EPS −$0.18
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$10.6M, EPS −$0.28
- Quarter ended Sep 30, 2025: revenue n/a, net income −$7.59M, EPS −$0.24
- Quarter ended Jun 30, 2025: revenue n/a, net income −$6.62M, EPS −$0.22
- Quarter ended Mar 31, 2025: revenue n/a, net income −$4.54M, EPS −$0.15
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$4.81M, EPS −$0.15
- Quarter ended Sep 30, 2024: revenue n/a, net income −$7.15M, EPS −$0.24
- Quarter ended Jun 30, 2024: revenue n/a, net income −$4.39M, EPS −$0.15
- Quarter ended Mar 31, 2024: revenue n/a, net income −$5.26M, EPS −$0.22
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$5.09M, EPS −$0.24
- Quarter ended Sep 30, 2023: revenue n/a, net income −$4.28M, EPS −$0.23
- Quarter ended Jun 30, 2023: revenue n/a, net income −$3.58M, EPS −$0.24
- Quarter ended Mar 31, 2023: revenue n/a, net income −$2.48M, EPS −$0.18
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$3.80M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$1.54M, EPS −$0.11
- Quarter ended Jun 30, 2022: revenue n/a, net income −$1.56M, EPS −$0.11
- Quarter ended Mar 31, 2022: revenue n/a, net income −$1.33M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$22.8M, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income −$403K, EPS n/a
IMMX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$23.9M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$14.6M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$11.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$7.41M, share buybacks $100.0K
- Fiscal year ended Dec 2021: operating cash flow −$1.59M, share buybacks n/a
IMMX balance sheet
- Jun 30, 2026: cash $225M, total assets $239M, total liabilities $10.2M, shareholders' equity $229M
- Mar 31, 2026: cash $79.3M, total assets $95.8M, total liabilities $11.5M, shareholders' equity $84.4M
- Dec 31, 2025: cash $93.9M, total assets $105M, total liabilities $11.0M, shareholders' equity $93.8M
- Sep 30, 2025: cash $15.9M, total assets $20.1M, total liabilities $11.8M, shareholders' equity n/a
- Jun 30, 2025: cash $11.6M, total assets $15.6M, total liabilities $11.0M, shareholders' equity $4.65M
- Mar 31, 2025: cash $15.9M, total assets $19.9M, total liabilities $10.3M, shareholders' equity $9.59M
- Dec 31, 2024: cash $17.7M, total assets $22.9M, total liabilities $9.70M, shareholders' equity $13.3M
- Sep 30, 2024: cash $19.7M, total assets $25.1M, total liabilities $7.59M, shareholders' equity $17.6M
Is IMMX profitable?
No. IMMIX BIOPHARMA INC lost $39.9M over the last four quarters.
What is IMMX's EPS?
Diluted earnings per share over the last four quarters were −$0.88; −$0.18 in the latest quarter.